Seeking Alpha

Covidien (COV) issues FY13 guidance, saying it expects revenues to increase 3% to 6% over the...

Covidien (COV) issues FY13 guidance, saying it expects revenues to increase 3% to 6% over the prior year, and its plans to spin off its pharmaceuticals business into a stand-alone public company are on track. Pharmaceutical sales are projected to be up 1% to 4%, and 4% to 7% in its medical devices segment. Operating margins should be in the 22% to 23% range with an effective tax rate of 18% to 19%.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs